Completed PHASE4 INTERVENTIONAL 2-arm NCT03349619

Nebulized Resveratrol Plus Carboxymethyl-β-Glucan for Reducing IL-5 in Children With Allergic Rhinitis (RENIM)

ReNIM Study - Nebulized Resveratrol Plus Carboxymethyl-β-Glucan for Reducing Nasal Interleukin-5 (IL-5) Measurements in Children With Allergic Rhinitis

Sponsor: Istituto per la Ricerca e l'Innovazione Biomedica

Conditions Allergic Rhinitis

Interventions Placebo Resveratrol plus Carboxymethyl-β-Glucan

Updated 9 times since 2017 Last updated: Dec 3, 2019 Started: Mar 5, 2018 Primary completion: Jul 31, 2018 Completion: Jul 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03349619, this PHASE4 trial focuses on Allergic Rhinitis and remains completed. Sponsored by Istituto per la Ricerca e l'Innovazione Biomedica, it has been updated 9 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2020 — Jan 2021 [monthly]

Completed PHASE4
Jul 2019 — Jan 2020 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Dec 2018 — Jul 2019 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jun 2018 — Dec 2018 [monthly]

Recruiting PHASE4
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Dec 2017 — Feb 2018 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Istituto per la Ricerca e l'Innovazione Biomedica

Data source: Istituto per la Ricerca e l'Innovazione Biomedica

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Palermo, Italy